70 completed. 70 Phase 2, 14 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 70 | Completed 70 |
| Phase 1 | 14 | Completed 14 |
| Phase 3 | 6 | Completed 6 |
Follow Vasculitis: new trials by email Literature Review of Vasculitis trials Research Report on Vasculitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dusquetide for the Treatment of Behcet's Disease Dusquetide - Behçet Disease | Phase 2 | Completed | Soligenix | 8 | 2024-11-18 | 2026-08-26 |
| Ustekinumab for Intestinal Behçet's Syndrome With Myelodysplastic Syndrome Ustekinumab 90 mg - Behcet's Syndrome, Intestinal Type, Myelodysplastic Syndrome | Phase 2 | Completed | Liu Tian | 8 | 2024-03-24 | 2026-05-13 |
| Upadacitinib for Refractory Behcet's Syndrome Upadacitinib 15 MG - Behcet Syndrome | Phase 2 | Completed | Liu Tian | 27 | 2024-01-25 | 2025-12-02 |
| JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease Ruxolitinib - Kohlmeier Degos Disease With Neurologic Involvement, Kohlmeier-Degos Disease | Phase 1 / Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 1 | 2023-09-28 | 2026-02-03 |
| Baricitinib for Refractory Takayasu Arteritis Baricitinib 4 MG - Takayasu Arteritis | Phase 2 | Completed | Liu Tian | 10 | 2023-04-03 | 2024-10-29 |
| Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With Anti-neutrophil Cytoplasmic Antibody(ANCA)-Associated Vasculitis BDB-001 injection, Cyclophosphamide, Glucocorticoids - ANCA-associated Vasculitis | Phase 1 / Phase 2 | Completed | Staidson (Beijing) Biopharmaceuticals Co., Ltd | 93 | 2022-02-22 | 2025-08-07 |
| Low-dose IL-2 Treatment on Behcet's Disease Low-dose IL-2, Placebo - Behcet's Disease | Phase 2 | Completed | HeJing | 60 | 2021-10-12 | 2024-04-03 |
| PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V Niclosamide, Placebo, Ciclesonide - Covid19 | Phase 2 / Phase 3 | Completed | Cambridge University Hospitals NHS Foundation Trust | 2240 | 2021-02-19 | 2025-06-20 |
| Use of Gallium-68 HA-DOTATATE PET/CT in Giant Cell Arteritis (GCA) 68-Ga HA-DOTATATE PET/CT - Giant Cell Arteritis | Phase 2 | Completed | University of Alberta | 9 | 2019-09-09 | 2023-10-18 |
| Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis. IFX-1, Placebo-IFX-1, Glucocorticoid (GC) - Granulomatosis With Polyangiitis (GPA), Microscopic Polyangiitis (MPA) | Phase 2 | Completed | InflaRx GmbH | 57 | 2019-04-03 | 2022-08-25 |
| Low Dose Naltrexone to Improve Physical Health in Patients With Vasculitis Naltrexone Hydrochloride, Placebo Comparator - Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS) | Phase 2 | Completed | University of Pennsylvania | 60 | 2019-02-04 | 2026-01-22 |
| A Placebo-controlled Phase 2 Trial to Investigate the Safety and Efficacy of Secukinumab in Giant Cell Arteritis Secukinumab 300 mg, s.c., Prednisolone, Placebo - Giant Cell Arteritis | Phase 2 | Completed | Novartis Pharmaceuticals | 52 | 2019-01-30 | 2023-08-21 |
| Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab Tocilizumab, Glucocorticoids - Giant Cell Arteritis | Phase 1 / Phase 2 | Completed | Insel Gruppe AG, University Hospital Bern | 18 | 2018-12-01 | 2021-06-22 |
| Acquired Immunodeficiency in ANCA Associated Vasculitis Pneumococcal Polysaccharide Conjugate vaccination and Pneumococcal Polysaccharide Vaccination - Systemic Vasculitis | Phase 2 | Completed | Cambridge University Hospitals NHS Foundation Trust | 114 | 2018-10-15 | 2026-09-08 |
| KPL-301 for Subjects With Giant Cell Arteritis mavrilimumab, placebo, prednisone - Giant Cell Arteritis | Phase 2 | Completed | Kiniksa Pharmaceuticals, Ltd. | 70 | 2018-09-20 | 2023-10-23 |
| EG-501 for Cognitive Impairment in Neuropsychiatric SLE (NPSLE): Efficacy and Safety Study Placebo, EG-501 - Neuropsychiatric Systemic Lupus Erythematosus, Systemic Lupus Erythematosus (SLE) | Phase 2 | Completed | Evergreen Therapeutics, Inc. | 131 | 2018-08-23 | 2025-12-15 |
| Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy PCV13, PPV23, Rituximab - Invasive Pneumococcal Infection | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 96 | 2018-02-05 | 2025-11-20 |
| Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies Pirfenidone - Pulmonary Fibrosis | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 7 | 2018-01-31 | 2025-11-20 |
| Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI) CLBS12, SOC - Critical Limb Ischemia, Buerger Disease | Phase 2 | Completed | Lisata Therapeutics, Inc. | 33 | 2017-11-01 | 2024-10-09 |
| Efficacy and Safety of Ustekinumab, a Human Monoclonal Anti-IL-12/IL-23 Antibody, in Patients With Behçet Disease Subcutaneous Ustekinumab - Behçet Disease | Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 16 | 2017-06-14 | 2025-09-08 |
Showing 20 of 70. Sign in to see all of them.
Behcet Syndrome (15) · Granulomatosis with Polyangiitis (15) · Giant Cell Arteritis (11) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (6) · Microscopic Polyangiitis (6) · Mucocutaneous Lymph Node Syndrome (6) · Uveitis (6) · Lupus Erythematosus, Systemic (5) · Churg-Strauss Syndrome (4) · Inflammation (4) · Chronic Limb-Threatening Ischemia (3) · Glomerulonephritis (3) · Recurrence (3) · Retinal Vasculitis (3)
Vascular Diseases (69) · Cardiovascular Diseases (68) · Skin and Connective Tissue Diseases (63) · Skin Diseases (61) · Skin Diseases, Vascular (60) · Immune System Diseases (41) · Autoimmune Diseases (37) · Systemic Vasculitis (22) · Nervous System Diseases (19) · Respiratory Tract Diseases (18) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (17) · Brain Diseases (17) · Central Nervous System Diseases (17) · Cerebrovascular Disorders (17)
Cyclophosphamide (8) · Rituximab (7) · Prednisone (6) · Glucocorticoids (5) · Etanercept (3) · Interleukin 1 Receptor Antagonist Protein (3) · Methylprednisolone (3) · Mycophenolic Acid (3) · Prednisolone (3) · mepolizumab (3) · Abatacept (2) · Azathioprine (2) · Daclizumab (2) · Interleukin-2 (2) · Methotrexate (2)
National Institute of Allergy and Infectious Diseases (NIAID) (7) · Assistance Publique - Hôpitaux de Paris (5) · Cambridge University Hospitals NHS Foundation Trust (5) · Amgen (3) · Liu Tian (3) · National Heart, Lung, and Blood Institute (NHLBI) (3) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (3) · Novartis Pharmaceuticals (3) · Insel Gruppe AG, University Hospital Bern (2) · Tehran University of Medical Sciences (2) · University of California, San Diego (2) · University of Pennsylvania (2) · Boston Children's Hospital (1) · Brigham and Women's Hospital (1) · Cairo University (1)
United States (31) · France (10) · United Kingdom (10) · Germany (9) · Canada (7) · China (5) · Netherlands (5) · Turkey (Türkiye) (5) · Italy (4) · Belgium (3) · Czechia (3) · Sweden (3) · Switzerland (3) · Iran (2) · Poland (2)
David Jayne (3) · Bahar Sadeghi, MD (2) · Carol A. Langford, MD, MHS (2) · Jane C Burns, MD (2) · John H. Stone, MD, MPH (2) · Peter A. Merkel, MD, MPH (2) · Adriana H Tremoulet, MD (1) · Ahmet Gul, MD (1) · Alison Clifford (1) · Anja Pfaff, PhD (1) · Arash Tehrani Banihashemi, MD, MPH (1)
PMID 12905485, PMID 15751091, PMID 15838068, PMID 15986348, PMID 16378799, PMID 16646004, PMID 19451574, PMID 19597921, PMID 19717547, PMID 20647199, PMID 20704622, PMID 20926833, PMID 22127969, PMID 22129253, PMID 22147444, PMID 22975753, PMID 23653652, PMID 23754238, PMID 23902481, PMID 24033923, PMID 24323392, PMID 24574239, PMID 25047592, PMID 25638011, PMID 25776953, PMID 25858045, PMID 25875256, PMID 26387933, PMID 26526721, PMID 26621483, PMID 26952547, PMID 27080929, PMID 27696762, PMID 27923814, PMID 27980877, PMID 28133925, PMID 28133931, PMID 28335798, PMID 28592297, PMID 29961816, PMID 30054122, PMID 30472651, PMID 30612116, PMID 31048415, PMID 31216123, PMID 32779863, PMID 33128347, PMID 34117737, PMID 34164952, PMID 34404463
2018 (2), 2014 (1), 2016 (1), 2017 (1), 268200700036C-5-0-1 (1), R01HL034545 (1), U54AR057319 (1)